Source MS Society: The European Medicines Agency (EMA) has recommended daclizumab, known as Zinbryta, be licensed to treat people with relapsing forms of MS.The National Institute for Health and Care Excellence (NICE) is now deciding whether to make this treatment available on the NHS in England and Wales. Read on.
Posts Categorized: MS Society Local Branch
MS Newsletter April – June 2016
news
MS Society local branch newsletter Jan-Mar 2016
MS newsletter Jan-Mar MS nomination form
MS Society local branch newsletter Nov/Dec 2015
MS newsletter Nov-Dec 2015
MS Society local branch newsletter Sept/Oct 2015
MS newsletter Sept-Oct 2015
MS Society local branch newsletter July/August 2015
MS newsletter July-August 2015
MS Society local branch newsletter May/June 2015
MS newsletter May-June 2015
MS Society local branch newsletter March/April 2015
 MS newsletter Mar-Apr 2015
MS Society local branch Newsletter Jan-Feb 2015
 MS newsletter Jan-Feb 2015 1
MS Society Oxford Branch Newsletter Nov-Dec 2014
MS newsletter Nov-Dec 2014